Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency.

Prime editing achieves up to 70% correction of GATA2 deficiency in human hematopoietic stem cells, enhancing engraftment and safety profiles.

• Why it matters: GATA2 deficiency causes severe immunodeficiency, and current gene editing methods face challenges like off-target effects and reduced cell engraftment, limiting therapeutic potential.
• What they did: Researchers used prime editing to correct a specific GATA2 mutation in patient-derived CD34+ hematopoietic stem and progenitor cells, optimizing conditions to preserve stemness and increase editing efficiency.
• The result: The approach resulted in increased functional GATA2 alleles, improved engraftment, limited off-target effects, and introduced PASSIGE, a versatile strategy for addressing GATA2-related mutations, advancing preclinical therapy development.